Prognostic impact of the timing of immunotherapy in first‐line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score‐matched analysis
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35447 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Yanxin Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Immunotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Postdoctoral lnnovation Project of Shandong Province, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Immunochemotherapy combinations have been the standard first‐line therapy for advanced lung adenocarcinoma (LUAD) without driver mutations, wherein concurrent chemotherapy and immunotherapy are conventionally anchored in the established dosing regimen. A few studies have suggested that the timing of immunotherapy in combinations may have a significant impact on the efficacy. However, this issue has not been addressed in an advanced LUAD cohort. We aimed to investigate the prognostic significance of the timing of immunotherapy in first‐line immunochemotherapy combinations for patients with advanced LUAD. We retrospectively analyzed 508 patients with advanced LUAD without driver mutations who received immunochemotherapy as initial systemic treatment. The patients were divided into two groups—the induction and non‐induction groups—with induction defined as receiving chemotherapy alone before concurrent immunochemotherapy. The bias between different groups was minimized using propensity score matching (PSM). We found both the PFS and OS of the patients in the induction group were significantly longer than those in the non‐induction group before (PFS: p < 0.0001, OS: p < 0.0001) and after PSM (PFS: p = 0.0045, OS: p = 0.00073). After adjusting for confounders, induction chemotherapy was still a significant favorable factor for both PFS ( p = 0.001) and OS ( p = 0.001). In subsequent analyses, we found that both ≥2‐cycles induction (PFS: p = 0.000, OS: p = 0.000) and 1‐cycle induction (PFS: p = 0.013, OS: p = 0.002) were superior to non‐induction and these differences were still significant after PSM. Our findings highlight the notable benefits of induction chemotherapy for patients with advanced LUAD treated with first‐line immunochemotherapy combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
- Phase I Clinical Trail Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
- Phase I Clinical Research Center, Shandong University Cancer Center, Jinan, Shandong, China.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
ORCID-Profile: Yuping Sun, Juan Li
Förderung
- National Natural Science Foundation of China
- Postdoctoral lnnovation Project of Shandong Province
- Natural Science Foundation of Shandong Province
- Jinan Science and Technology Development Program
- Key Technology Research and Development Program of Shandong Province
- Beijing Science and Technology Innovation Medical Development Foundation
- Beijing Xisike Clinical Oncology Research Foundation
- Wu Jieping Medical Foundation
Zitieren
APA
Sun, Y., Deng, Z., Sun, H., Wei, X., Wang, L., Wang, S., Gao, A., Sun, Y., & Li, J. (2025). Prognostic impact of the timing of immunotherapy in first‐line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score‐matched analysis. International Journal of Cancer. https://doi.org/10.1002/ijc.35447
Vancouver
Sun Y, Deng Z, Sun H, Wei X, Wang L, Wang S, et al. Prognostic impact of the timing of immunotherapy in first‐line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score‐matched analysis. International Journal of Cancer. 2025. doi:10.1002/ijc.35447
BibTeX
@article{Sun2025,
author = {Sun, Yanxin and Deng, Zhenzhen and Sun, Haifeng and Wei, Xiaojuan and Wang, Leirong and Wang, Shuyun and Gao, Aiqin and Sun, Yuping and Li, Juan},
title = {Prognostic impact of the timing of immunotherapy in first‐line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score‐matched analysis},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35447}
}
EUVIMED